Harvard Bioscience (HBIO) Other Accumulated Expenses (2010 - 2026)

Harvard Bioscience (HBIO) has reported Other Accumulated Expenses for 17 consecutive years, with $14.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 896.66% year-over-year to $14.9 million; the TTM figure through Mar 2026 stood at $14.9 million (up 896.66% YoY), while the FY2025 annual figure was $1.4 million, down 84.85% from the prior year.
• Other Accumulated Expenses climbed to $14.9 million in Q1 2026 per HBIO's latest filing, from $1.4 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $14.9 million in Q1 2026 and bottomed at $736000.0 in Q2 2024.
• Historically, Other Accumulated Expenses has averaged $5.4 million across 5 years, with a median of $1.7 million in 2022.
• Annual changes were most pronounced in 2024 — Other Accumulated Expenses plunged 91.86% — and 2026, when it jumped 896.66%.
• Harvard Bioscience's Other Accumulated Expenses stood at $7.5 million in 2022, then jumped by 41.88% to $10.6 million in 2023, then slipped by 11.41% to $9.4 million in 2024, then tumbled by 84.85% to $1.4 million in 2025, then surged by 946.32% to $14.9 million in 2026.
• Business Quant data shows HBIO's Other Accumulated Expenses at $14.9 million in Q1 2026, $1.4 million in Q4 2025, and $1.6 million in Q3 2025.